HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KPRX
Kiora Pharmaceuticals, Inc.
There isn't enough reported data to score KPRX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KPRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
KPRX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KPRX PE Valuation
KPRX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KPRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect KPRX's losses to shrink, with revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
KPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.79 | -$0.53 |
| Q2 2026 | -$2.50 | +$0.58 |
| Q1 2026 | -$2.70 | +$0.37 |
| Q4 2025 | -$2.64 | -403% |
| Q3 2022 | -$367.47 | +$183.33 |
| Q2 2022 | -$417.60 | +$187.20 |
| Q1 2022 | -$478.80 | +$136.80 |
| Q4 2021 | -$514.80 | +$122.40 |
KPRX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over KPRX on profitability, with a higher operating margin.
KPRX Quarterly Revenue
KPRX's revenue is growing: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -169% | N/A |
| Q2 2024 | -12724% | N/A |
| Q1 2024 | 83% | N/A |
HIMS has the edge over KPRX on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
KPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$557.9K | +$715.6K |
| Q1 2026 | -$3.2M | -$462.2K |
| Q4 2025 | -$2.3M | -$51.3K |
| Q3 2025 | -$1.3M | -238% |
| Q1 2025 | -$2.7M | -120% |
| Q4 2024 | -$2.2M | +$374K |
| Q3 2024 | $920.1K | +$3.4M |
| Q1 2024 | $13.6M | +$16.7M |
KPRX has burned cash in almost every quarter: −$8M over the past year, against −$5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over KPRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +117K shares |
| 1 year | +44% | +1.9M shares |
| 3 years | +2940% | +6.1M shares |
| 5 years | +49822% | +6.3M shares |
KPRX has 6M diluted shares, up 44% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
KPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -0.8x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -2.5x | Net Cash |
| Q1 2024 | -12.0x | Net Cash |
KPRX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.6 | Oversold |
| Stochastic | 1.2 | Oversold |
KPRX's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KPRX PE vs Healthcare Sector
KPRX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.09 | 36% below |
| 20 week MA | $2.40 | 45% below |
| 50 week MA | $2.31 | 42% below |
| 100 week MA | $2.64 | 50% below |
| 200 week MA | $6.48 | 79% below |
KPRX is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
KPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,351.6 | $2,138.4 | -36% |
| 2021 | $2,138.4 | $312.5 | -85% |
| 2022 | $312.5 | $22.1 | -93% |
| 2023 | $22.1 | $4.70 | -79% |
| 2024 | $4.70 | $3.29 | -30% |
| 2025 | $3.29 | $1.97 | -40% |
| 2026 YTD | $1.97 | $1.33 | -32% |
KPRX has the edge over HIMS on returns for 2026, with the stronger performance.